COBRE: OK MED RES FOUND: CORE IV: MRI IMAGING IN VIVO

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 MRI/MRS核心设施的总体目标是提供非侵入性体内监测能力，可用于评估大多数疾病发病机制进展阶段发生的形态学、生理学、病理生理学和代谢过程。MRI/MRS核心设施的一个主要重点是在实验转基因小鼠或大鼠模型中研究心血管疾病各个方面的体内发病机制。5个拟议项目中至少有3个将利用MRI/MRS核心设施作为主要组成部分，并从磁共振成像（MRI）和/或磁共振波谱（MRS）研究中获益匪浅。其余2个拟定项目可能在未来拟定的体内项目中使用MRI和/或MRS技术。因此，最重要的是建立MRI/MRS核心，并直接与每个研究人员进行互动，如下文进一步详细讨论的那样。所述核心将能够在体内特异性地提供（1）形态学评估，其将提供任何心血管相关组织或血管中高达100 μ m分辨率的“微观”组织学信息，（2）以磁共振血管造影术形式的血管特异性图像，（3）血管流速，（4）使用最近开发的血管特异性造影剂的心血管发病机理的造影剂图像增强，（5）使用新开发的标记有造影剂的单克隆抗体对参与心血管疾病发病机制的特异性内皮受体进行造影剂图像增强，和（6）与组织损伤或生物能量学变化有关的代谢过程。MRI/MRS核心机构将在新提议的位于贝尔大楼的俄克拉荷马州医学研究基金会MRI/MRS机构内建立，由Dr. Rheal A.托纳。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The general objective of the MRI/MRS Core facility is to provide non-invasive in vivo monitoring capabilities that can be used to assess morphological, physiological, pathophysiological and metabolic processes that occur during progressive stages of the pathogenesis of most diseases. A major focus of the MRI/MRS Core facility is to study the in vivo pathogenesis of various aspects of cardiovascular diseases in experimental transgenic mice or rat models. At least three of the 5 proposed projects will utilize the MRI/MRS Core facility as a major component and significantly benefit from magnetic resonance imaging (MRI) and/or magnetic resonance spectroscopy (MRS) studies. The remaining 2 proposed projects will possibly use MRI and/or MRS techniques in future proposed in vivo projects. As a result it is of the utmost importance that the MRI/MRS Core is established and that it directly interacts with each of the researchers respective to the proposed projects as discussed in further detail below. The core will be able to specifically provide in vivo (1) morphological assessment that will provide "microscopic" histology information in any cardiovascular-associated tissue or vascular vessel up to 100 #m resolution, (2) vascular specific images in the form of magnetic resonance angiography, (3) vascular flow velocity, (4) contrast agent image enhancement of cardiovascular pathogenesis with the use of recently-developed vascular-specific contrast agents, (5) contrast agent image enhancement of specific endothelial receptors that are involved in the pathogenesis of a cardiovascular disease using newlydeveloped monoclonal antibodies tagged with a contrast agent, and (6) metabolic processes relating to changes in either tissue injury or bioenergetics. The MRI/MRS Core facility will be established in the newly-proposed Oklahoma Medical Research Foundation MRI/MRS Facility located in the Bell Building, under the direction of Dr. Rheal A. Towner.